Log in to save to my catalogue

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammato...

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammato...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8137624

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

About this item

Full title

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Publisher

Singapore: Springer Singapore

Journal title

Journal of gastroenterology, 2021-06, Vol.56 (6), p.560-569

Language

English

Formats

Publication information

Publisher

Singapore: Springer Singapore

More information

Scope and Contents

Contents

Background
This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD).
Methods
Patients with moderate-to-severe IBD initiated on adalimumab therapy were enrolled herein. Serum LRG, C-reactive pr...

Alternative Titles

Full title

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8137624

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8137624

Other Identifiers

ISSN

0944-1174,1435-5922

E-ISSN

1435-5922

DOI

10.1007/s00535-021-01793-0

How to access this item